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1. INTRODUCTION
Cardiovascular disease (mainly stroke and coronary artery disease) 
remains an important global cause of morbidity and mortality 
and hypertension is a major contributing risk factor, particularly 
in older people [1,2]. The overall prevalence of hypertension in all 
adults in England, UK is 28.4% and this compares with a preva-
lence of 66.5% in patients over 75 years of age with trends covering 
2003–2015 showing little change [2]. With an ageing population 
and the greatest expansion in population expected in the over 65 
age group, hypertension will become a more prominent treatable 
and preventable cause of premature death [3].
There has been controversy regarding the appropriateness of treat-
ment of hypertension in older people based on data from epidemi-
ological studies, which suggest that there is a higher risk of death in 
patients over 80 years of age with lower Blood Pressure (BP) [4–6]. 
This notion has been challenged by data from the Syst-Eur and the 
HYpertension in the Very Elderly Trial (HYVET) studies which 
showed that antihypertensive treatment in persons 60 and 80 years 
or older respectively, is beneficial [7,8]. More recently, the SPRINT 
trial has demonstrated that lowering the BP to a target systolic BP 
of <120 mmHg is beneficial in patients aged over 75 years [9]. As a 
result, guidelines recommend BP control to reduce cardiovascular 
risk, irrespective of the age of the patient [10–12].
Current NICE guidelines for the diagnosis and treatment of hyperten-
sion recommend the widespread use of Ambulatory Blood Pressure 
Monitoring (ABPM) and Home BPM (HBPM) in order to exclude 
the presence of White Coat Hypertension (WCH), as the benefits of 
treatment are yet unproven [10]. WCH is defined as persistently raised 
clinic blood pressure readings (≥140/90 mmHg) in individuals who 
have normal HBPM or ABPM readings (<135/85 mmHg) and may 
affect up to 50% of the population, according to some studies [13,14]. 
Interestingly, up to 42% of patients who have WCH go on to develop 
sustained hypertension [13]. Evidence for a role for the active treat-
ment of WCH has been contentious as some research results do not 
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A B S T R AC T
The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of benefit of the treatment 
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 support protection against cardiovascular events [15]. However, a study 
by Franklin et al. [16] suggests that men and diabetics with untreated 
WCH are at increased risk. Furthermore, the HYVET ambulatory 
blood pressure sub study analysis estimates that 50% of patients in 
the main study may have had WCH [17]. It is therefore as yet 
unknown whether the patients with WCH benefit from treatment.
1.1. Aim
HYpertension in the Very Elderly Trial 2 is a feasibility study, which 
serves as a prelude to a definitive randomized controlled trial, in 
order to determine whether the treatment of WCH in the very 
elderly is feasible and outweighs any adverse events.
1.2. Outcomes
HYpertension in the Very Elderly Trial 2 focuses on the following 
outcomes:
 • Estimation of the proportion of eligible patients that can be 
recruited from initial screening.
 • Exploration of different methods of identifying/recruiting patients.
 • Determination of the willingness of General Practices (GPs) to 
recruit and randomize patients and the willingness of patients to 
be randomized.
 • Recruitment rate.
 • Adherence to the treatment protocol.
 • Withdrawal from the trial.
 • Expanding the opportunities for Patient and Public Involvement 
(PPI) in the research design and its subsequent conduct and dis-
semination.
 • Ambulatory and home blood pressure monitoring and whether 
or not the patient achieves their target blood pressure.
 • Composite of cardiovascular events and stroke.
2. MATERIALS AND METHODS
2.1. Design
This is a multi-center, open-label study assessing the feasibility of 
conducting a randomized controlled trial to treat WCH in the very 
elderly. It entails a 1:1 randomization of patients to a treatment 
arm with established antihypertensive drugs (Indapamide MR and 
Perindopril Erbumine) [18,19] and control arm (no treatment) 
which is the current standard of care (Figure 1). This design will 
gather preliminary information on the intervention and the feasi-
bility of conducting a full-scale randomized controlled trial.
A local PPI group has reviewed the patient facing documents for 
the trial and a lay member of the public sits on the Trial Steering 
Committee.
2.2. Trial Setting
HYpertension in the Very Elderly Trial 2 will be run from a number 
of GPs and will be supported by the Primary Care Clinical Research 
Network (CRN) in the Kent, Surrey and Sussex regions of the UK. 
Suitable GPs will be identified by the CRN and will then identify 
potentially suitable participants from their patient databases and 
will be responsible for the recruitment and follow up in accordance 
with the study protocol.
2.3. Population and Sample Size
One hundred participants will be randomized for this feasibility 
study after having been confirmed with WCH based on ABPM 
or HBPM. A sample size calculation has not been performed as 
HYVET 2 is a feasibility study and simple descriptive statistics will 
be presented, i.e. frequencies and percentages for binary and cate-
gorical variables and means and standard deviations for normally 
distributed variables and medians and interquartile ranges for 
skewed continuous variables. A more detailed statistical analysis 
plan will be agreed and signed off prior to final data analysis.
2.4. Inclusion Criteria
 • Participants ≥75 years of age.
 • Clinic sitting systolic BP ≥150 mmHg but <200 mmHg and a 
diastolic BP <110 mmHg.
 • Established diagnosis of WCH - confirmed if the mean ambulatory 
day time systolic BP is <135 mmHg and diastolic BP is <85 mmHg 
(from at least 14 measurements) or from an average HBPM from 
BP readings twice a day for at least 5 days (ideally 7 days).
 • Not prescribed drug therapy indicated for treatment of hyperten-
sion within the last 6 months.
 • Capacity to consent.
 • Ability to comply with the protocol and additional study visits 
and assessments.
2.5. Exclusion Criteria
 • Contraindication to the use of Indapamide MR and Perindopril 
in accordance with the summary of product characteristics.
 • Regular non-steroidal anti-inflammatory drug (NSAID) use. 
Regular use being defined by the local GPs with consideration to 
cardiovascular risk and blood pressure.
Figure 1 | Treatment schedule.
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 • Hypertensive emergency.
 • Secondary hypertension.
 • Postural hypotension (postural drop in systolic BP ≥20 mmHg or 
postural symptoms at screening).
 • Any stroke or myocardial infarction in the previous 6 months.
 • Heart failure requiring treatment with drugs having an antihy-
pertensive effect.
 • Previous documented evidence of gout.
 • estimated Glomerular Filtration Rate (eGFR) <30 ml/min.
 • Montreal cognitive assessment score (MoCA) <22.
 • Life expectancy <1 year due to malignancy or chronic disease.
2.6. Recruitment
HYpertension in the Very Elderly Trial 2 will recruit initially from 
GPs based in the Kent, Surrey and Sussex CRN region of the UK. 
Each GPs will aim to recruit at least two patients over a 1-year 
period. This will allow accurate determination of the total number 
of GPs required for the definitive trial.
Eligible participants will be identified from the GPs electronic 
records, as well as those who have had ABPM and/or HBPM in 
the last 2 years and have not been prescribed drug therapy indi-
cated for treatment of hypertension within the last 6 months. 
These patients will be invited to participate in the trial via a mail 
out from the GPs. The Patient Information Sheet will be sent out 
to potential participants along with a covering letter introducing 
the study. A follow-up phone call will be made to the potential 
participant to determine whether they are interested in partici-
pating in the trial or the participant may phone the local research 
contact if preferred. In addition, opportunistic recruitment will 
also be possible.
For those patients that are eligible but not randomized, anonymized 
information will be collected where appropriate to document why 
randomization did not occur on a HYVET 2 Screening Log. This is 
an important information for a feasibility trial.
2.7. Obtaining Informed Consent
Written informed consent forms will be personally signed and 
dated by the participant as well as the medical practitioner 
receiving consent. The person who provides the initial infor-
mation should not be the same person who receives consent. 
If the participant is unable to sign the consent form, then an 
attempt to mark the document should be encouraged and a wit-
ness statement and signature provided by a carer (or equivalent) 
of the participant. If the participant loses capacity during the 
trial, the original consent endures the loss of capacity providing 
that the trial has not significantly altered. Once a participant has 
consented to the trial, they will be allocated a unique Participant 
Identification Number (PIN). These details will be logged on 
the Subject Identification Log. This document must remain at 
the investigator site at all times. Copies must not be sent to the 
Clinical Trials Unit.
2.8. Randomization and Group Allocation
After a medically qualified professional has checked and signed 
off that the participant is eligible for the study, they will be ran-
domized to a trial arm. Randomization will be performed using the 
web-based system ‘Sealed Envelope’ (https://www.sealedenvelope.
com/). The HYVET 2 Randomization Guide details how to log on 
to randomize a participant.
Simple randomization will be used, with a 1:1 allocation ratio. 
The allocation will be concealed. The randomization service 
providers generate a randomization list and upload it to the 
system. As each participant is entered onto the system by the 
site, the next randomization allocation is revealed. The next allo-
cation in the sequence is concealed until irreversibly assigned to 
a participant.
Once randomization has been performed by the site, a randomiza-
tion notification email detailing date of randomization, trial arm 
and PIN number will be sent to the randomizer and the trial man-
agement team.
Participants will be randomized to either arm of the study as 
described above.
2.9. Study Interventions
A summary of study interventions is highlighted in Table 1.
2.10. Clinic BP
Clinic BP measurement will be performed using an internation-
ally validated automated oscillometric sphygmomanometer – e.g. 
Omron 705 cp-II.
 • The participant should not have exercised, eaten or smoked for at 
least half an hour prior to taking blood pressure.
 • The arm must be free of tight clothing and supported at heart level.
 • The correct cuff size must be used, to avoid over or under esti-
mating BP.
 • BP will be measured in both arms at visit 1. Future BPs will be 
measured in arm with highest BP if there is 20/10 mmHg differ-
ence. The arm used must be documented.
 • BP will be measured twice sitting and twice standing; (using an 
internationally validated automated device), after an initial rest 
of 5 min with 1 min between each reading.
 • The participant will be asked not to talk during the procedure.
2.11.  Home Blood Pressure Monitoring and 
Ambulatory Blood Pressure Monitoring
Participants with a mean sitting clinic systolic BP ≥150 mmHg 
but <200 mmHg and diastolic BP <110 mmHg from visits 1 and 
2, will be offered a 24-h ABPM or HBPM. WCH is confirmed if 
the mean awake ambulatory systolic BP is <135 mmHg and mean 
awake ambulatory diastolic BP is <85mmHg (from at least 14 
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3. DATA ANALYSIS
Data will be exported from the MACRO by the data manager in 
Stata 14 format (or higher) and imported into Stata where descrip-
tive analyses will be undertaken by the trial statistician.
As this is a feasibility trial, simple descriptive statistics will be pre-
sented i.e. frequencies and percentages for binary and categorical 
variables and means and standard deviations for normally distrib-
uted variables and medians and interquartile ranges for skewed 
continuous variables. A more detailed statistical analysis plan will 
be agreed and signed off prior to final data analysis.
Patient flow through the trial will be shown in a CONSORT dia-
gram in accordance with the CONSORT extention for pilot and 
feasibility studies (Figure 2).
Apart from the feasibility outcomes stated above no other pri-
mary outcome is specified and secondary outcome, subgroup and 
adjusted analyses are not applicable. Furthermore, neither interim 
analysis nor early stopping criteria are planned.
There will be a large degree of uncertainty around the propor-
tion of Serious Adverse Reactions (SARs) as it is anticipated that 
these would be rare. To illustrate this, SARs attributable to the 
Investigational Medicinal Product (IMP) listed on the patient’s 
information leaflet are presented with likely frequencies [18,19]. 
With only 50 patients receiving IMP in this study, the 95% confi-
dence interval around the event rate will be so wide that we would 
be most unlikely to detect an exaggerated event rate, this being the 
basis of a stopping rule.
4. LIMITATIONS OF STUDY
Currently WCH is a condition that is not treated; hence, a major 
issue will be to convince eligible participants to be part of the study. 
Older patients often already take multiple medication, so adding 
more medication might be challenging. Locating patients from 
GPs databases will also be an issue given the fact that WCH is a 
condition is not treated and often not documented as a diagnosis. 
To address these issues we have on our team general practitioners 
with expertise in primary care systems which will help identify eli-
gible patients. The study is conducted with support from trained 
research nurses who will explain the benefits versus adverse effects 
to patients in detail. Primary care CRN are part of the study and are 
also helping to address the above issues.
Another limitation is that the pharmacological treatment (inda pamide 
± perindopril) chosen for this study is not strictly in line with the NICE 
guidelines for the treatment of hypertension. The reasoning behind 
this treatment regimen is that it was used in the HYVET trial and has 
been demonstrated to be effective for the treatment of hypertension 
in the very elderly. This approach also allows for comparison of treat-
ment effects in HYVET versus HYVET 2. In an attempt mitigate this 
issue, research investigators have visited trial sites in order to explain 
the rationale and are readily available to discuss any queries.
5. ETHICS, DISSEMINATION AND IMPACT
Ethics approval has been acquired from Regional Ethics Committee 
Westminster, London (Reference No: 18/LO/0104) for the trial 
measurements) or from HBPM from BP readings twice a day for 
at least 5 days. If ABPM or HBPM identifies participants that have 
sustained hypertension (defined as average BP ≥135/85) they will 
be referred back to the GPs for standard clinical care and will 
excluded from the study.
Ambulatory Blood Pressure Monitoring will be performed by par-
ticipants at screening visit 2 (Table 1). The participant will be asked 
to wear the ABPM for a period of 24 h at home, if tolerated. It will 
then be returned to the GPs practice on completion. For those who 
agree to be fitted with the ABPM a guidance leaflet will be issued 
detailing the management of the ABPM before, during and after 
the procedure.
Home blood pressure monitoring will be recorded for all partici-
pants in the week prior to follow-up visits (Table 1). The BP read-
ings will be recorded twice a day for 5 days, morning and evening at 
9 am and 6 pm ±2 h and documented in the HBPM chart provided. 
A guidance leaflet will be issued to all participants with instruc-
tions on how to record and document the HPBM.
The preferred option is that all participants undertake the ABPM; 
however, if participants do not wish to undertake an ABPM they 
will be asked to undertake only HBPM. About 24 h ABPM will 
be measured using a Diasys Integra II recorder (Novacor®, Cedex, 
France) or another internationally validated device as in the 
HYVET study [7]. HBPM will be measured by an internationally 
validated BP device.
2.12. Blood Tests
General practices will perform biochemical and hematological 
blood samples which will be analyzed using validated laboratory 
techniques and assays at local laboratories of the recruiting 
centers.
2.13. Electrocardiogram (ECG)
12-Lead ECGs will be performed using validated machines avail-
able at the recruiting centers.
2.14. Post Study Follow-up
Two years after the participant has stopped the treatment, follow-up 
information will be gathered from the GPs records for each par-
ticipant, where available. This will include documenting whether 
the participant is alive or deceased and whether any cardiovascular 
outcomes have occurred. The participant is not contacted directly 
for this follow-up.
2.15. Withdrawal Criteria
Each participant has the right to withdraw at any time without 
giving reason but other reasons for withdrawal from the treatment 
might include postural hypotension and adverse events related to 
the drug treatment in the intervention arm. If the participant is 
withdrawn, then if at all possible an Early Termination Visit will 
be performed.
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protocol, informed consent forms and other relevant documents 
e.g. advertisements and GPs information letters. It is registered 
on ISRCTN (ISRCT No: 13127656). Substantial amendments that 
require review by REC will not be implemented until the REC 
grants a favorable opinion for the trial. All correspondence with the 
REC will be retained in the Trial Master File/Investigator Site File.
Results of this study will be presented at conferences such as the 
British and Irish Hypertension Society and the European Society 
for Hypertension. We also intend to submit articles to peer reviewed 
journals. In addition, results will be disseminated to participants, 
patients and the general public through the PPI and relevant com-
munity groups.
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